Transfusions after nonmyeloablative or reduced-intensity conditioning regimens.

ABO Blood-Group System/immunology; Blood Group Incompatibility; Erythrocyte Transfusion; Erythropoietin/therapeutic use; Granulocyte Colony-Stimulating Factor/therapeutic use; Hematopoietic Stem Cell Transplantation; Humans; Platelet Transfusion; Transplantation Conditioning; Transplantation, Homologous

Disciplines :

Hematology

Author, co-author :

Baron, Frédéric ; Centre Hospitalier Universitaire de Liège - CHU > Hématologie clinique

Vanstraelen, Gaëtan

Beguin, Yves ; Centre Hospitalier Universitaire de Liège - CHU > Hématologie clinique

Language :

English

Title :

Transfusions after nonmyeloablative or reduced-intensity conditioning regimens.

Publication date :

2006

Journal title :

Leukemia

ISSN :

0887-6924

eISSN :

1476-5551

Publisher :

Nature Publishing Group, London, United Kingdom

Volume :

Issue :

Pages :

2081-6

Peer reviewed :

Peer Reviewed verified by ORBi

Available on ORBi :

since 25 February 2009

Statistics

Number of views

56 (0 by ULiège)

Number of downloads

170 (0 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenCitations

OpenAlex citations

Bibliography

Giralt S. Reduced-intensity conditioning regimens for hematologic malignancies: What have we learned over the last 10 years? Hematology 2005; 2005: 384-389.
Kottaridis PD, Milligan DW, Chopra R, Chakraverty RK, Chakrabarti S, Robinson S et al. In vivo CAMPATH-1H prevents graftversus-host disease following nonmyeloablative stem cell transplantation. Blood 2000; 96: 2419-2425.
Slavin S, Nagler A, Naparstek E, Kapelushnik Y, Aker M, Cividalli G et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 1998; 91: 756-763.
Childs R, Clave E, Contentin N, Jayasekera D, Hensel N, Leitman S et al. Engraftment kinetics after nonmyeloablative allogeneic peripheral blood stem cell transplantation: Full donor T-cell chimerism precedes alloimmune responses. Blood 1999; 94: 3234-3241.
McSweeney PA, Niederwieser D, Shizuru JA, Sandmaier BM, Molina AJ, Maloney DG et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: Replacing highdose cytotoxic therapy with graft-versus-tumor effects. Blood 2001; 97: 3390-3400.
Baron F, Sandmaier BM. Chimerism and outcomes after hematopoietic cell transplantation following nonmyeloablative conditioning. Leukemia 2006, July 27 [E-pub ahead of print].
Baron F, Maris MB, Sandmaier BM, Storer BE, Sorror M, Diaconescu R et al. Graft-versus-tumor effects after allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning. J Clin Oncol 2005; 23: 1993-2003.
Baron F, Storb R. Allogeneic hematopoietic cell transplantation following nonmyeloablative conditioning as treatment for hematologic malignancies and inherited blood disorders (Review). Mol Ther 2006; 13: 26-41.
Kerbauy FR, Storb R, Hegenbart U, Gooley T, Shizuru J, Al-Ali HK et al. Hematopoietic cell transplantation from HLA-identical sibling donors after low-dose radiation-based conditioning for treatment of CML. Leukemia 2005; 19: 990-997.
Maris MB, Sandmaier BM, Storer BE, Maloney DG, Shizuru JA, Agura E et al. Unrelated donor granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cell transplantation after nonmyeloablative conditioning: The effect of postgrafting mycophenolate mofetil dosing. Biol Blood Marrow Transplant 2006; 12: 454-465.
Khouri IF, Saliba RM, Giralt SA, Lee M-S, Okoroji G-J, Hagemeister FB et al. Nonablative allogeneic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma: Low incidence of toxicity, acute graft-versus-host disease, and treatment-related mortality. Blood 2001; 98: 3595-3599.
Sorror ML, Leisenring W, Deeg HJ, Martin PJ, Storb R. Twenty-year follow-up in patients with aplastic anemia given marrow grafts from HLA-identical siblings and randomized to receive methotrexate/ cyclosporine or methotrexate alone for prevention of graft-versus-host disease (Letter to the Editor). Biol Blood Marrow Transplant 2005; 11: 567-568.
Giralt S, Thall PF, Khouri I, Wang X, Braunschweig I, Ippolitti C et al. Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation. Blood 2001; 97: 631-637.
Mohty M, de Lavallade H, Ladaique P, Faucher C, Vey N, Coso D et al. The role of reduced intensity conditioning allogeneic stem cell transplantation in patients with acute myeloid leukemia: A donor vs no donor comparison. Leukemia 2005; 19: 916-920.
Shimoni A, Kröger N, Zabelina T, Ayuk F, Hardan I, Yeshurun M et al. Hematopoietic stem-cell transplantation from unrelated donors in elderly patients (age >55 years) with hematologic malignancies: Older age is no longer a contraindication when using reduced intensity conditioning. Leukemia 2005; 19: 7-12.
Appelbaum FR. Dose intensity and the toxicity and efficacy of allogeneic hematopoietic cell transplantation (Keynote Address). Leukemia 2005; 19: 171-175.
Baron F, Fillet G, Beguin Y. Erythropoiesis after nonmyeloablative stem-cell transplantation is not impaired by inadequate erythropoietin production as observed after conventional allogeneic transplantation. Transplantation 2002; 74: 1692-1696.
Weissinger F, Sandmaier BM, Maloney DG, Bensinger WI, Gooley T, Storb R. Decreased transfusion requirements for patients receiving nonmyeloablative compared with conventional peripheral blood stem cell transplants from HLA-identical siblings. Blood 2001; 98: 3584-3588.
Sorror ML, Maris MB, Storer B, Sandmaier BM, Diaconescu R, Flowers C et al. Comparing morbidity and mortality of HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative and myeloablative conditioning: Influence of pretransplant comorbidities. Blood 2004; 104: 961-968.
Ivanov V, Faucher C, Mohty M, Bilger K, Ladaique P, Sainty D et al. Decreased RBCTs after reduced intensity conditioning allogeneic stem cell transplantation: Predictive value of prior Hb level. Transfusion 2004; 44: 501-508.
Le Blanc K, Remberger M, Uzunel M, Mattsson J, Barkholt L, Ringden O. A comparison of nonmyeloablative and reduced-intensity conditioning for allogeneic stem-cell transplantation. Transplantation 2004; 78: 1014-1020.
Canals C, Muniz-Diaz E, Martinez C, Martino R, Moreno I, Ramos A et al. Impact of ABO incompatibility on allogeneic peripheral blood progenitor cell transplantation after reduced intensity conditioning. Transfusion 2004; 44: 1603-1611.
Seebach JD, Stussi G, Passweg JR, Loberiza Jr FR, Gajewski JL, Keating A et al. ABO blood group barrier in allogeneic bone marrow transplantation revisited. Biol Blood Marrow Transplant 2005; 11: 1006-1013.
Barge AJ, Johnson G, Witherspoon R, Torok-Storb B. Antibody-mediated marrow failure after allogenic bone marrow transplantation. Blood 1989; 74: 1477-1480.
Baron F, Baker JE, Storb R, Gooley TA, Sandmaier BM, Maris MB et al. Kinetics of engraftment in patients with hematologic malignancies given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. Blood 2004; 104: 2254-2262.
Bolan CD, Leitman SF, Griffith LM, Wesley RA, Procter JL, Stroncek DF et al. Delayed donor red cell chimerism and pure red cell aplasia following major ABO-incompatible nonmyeloablative hematopoietic stem cell transplantation. Blood 2001; 98: 1687-1694.
Mielcarek M, Leisenring W, Torok-Storb B, Storb R. Graft-versus-host disease and donor-directed hemagglutinin titers after ABO-mismatched related and unrelated marrow allografts: Evidence for a graft-versus-plasma cell effect. Blood 2000; 96: 1150-1156.
Griffith LM, McCoy Jr JP, Bolan CD, Stroncek DF, Pickett AC, Linton GF et al. Persistence of recipient plasma cells and antidonor isohaemagglutinins in patients with delayed donor erythropoiesis after major ABO incompatible non-myeloablative haematopoietic cell transplantation. Br J Haematol 2005; 128: 668-675.
Kroger N, Zagrivnaja M, Schwartz S, Badbaran A, Zabelina T, Lioznov M et al. Kinetics of plasma-cell chimerism after allogeneic stem cell transplantation by highly sensitive real-time PCR based on sequence polymorphism and its value to quantify minimal residual disease in patients with multiple myeloma. Exp Hematol 2006; 34: 688-694.
Zaucha JM, Mielcarek M, Takatu A, Little M-T, Gooley T, Baker J et al. Engraftment of early erythroid progenitors is not delayed after non-myeloablative major ABO-incompatible haematopoietic stem cell transplantation. Br J Haematol 2002; 119: 740-750.
Peggs KS, Morris EC, Kottaridis PD, Geary J, Goldstone AH, Linch DC et al. Outcome of major ABO-incompatible nonmyeloablative hematopoietic stem cell transplantation may be influenced by conditioning regimen. Blood 2002; 99: 4642-4643.
Beguin Y, Clemons GK, Oris R, Fillet G. Circulating erythropoietin levels after bone marrow transplantation: Inappropriate response to anemia in allogeneic transplants. Blood 1991; 77: 868-873.
Link H, Boogaerts MA, Fauser AA, Slavin S, Reiffers J, Gorin NC et al. A controlled trial of recombinant human erythropoietin after bone marrow transplantation. Blood 1994; 84: 3327-3335.
Baron F, Sautois B, Baudoux E, Matus G, Fillet G, Beguin Y. Optimization of recombinant human erythropoietin therapy after allogeneic hematopoietic stem cell transplantation. Exp Hematol 2002; 30: 546-554.
Ivanov V, Faucher C, Mohty M, Bilger K, Ladaique P, Sainty D et al. Early administration of recombinant erythropoietin improves hemoglobin recovery after reduced intensity conditioned allogeneic stem cell transplantation. Bone Marrow Transplant 2005; 36: 901-906.
Vanstraelen G, Baron F, Willems E, Bonnet C, Hafraoui K, Frère P et al. Recombinant human erythropoietin therapy after allogeneic hematopoietic cell transplantation with a nonmyeloablative conditioning regimen: Low donor chimerism predicts for poor response. Exp Hematol 2006; 34: 841-850.
Mohty M, Faucher C, Blaise D. Graft-versus-host-disease and granulocyte colony-stimulating factor administration after allogeneic stem cell transplantation. Leukemia 2005; 19: 500-503.
Wong R, Giralt SA, Martin T, Couriel DR, Anagnostopoulos A, Hosing C et al. Reduced-intensity conditioning for unrelated donor hematopoietic stem cell transplantation as treatment for myeloid malignancies in patients older than 55 years. Blood 2003; 102: 3052-3059.
Baron F, Maris MB, Storer BE, Sandmaier BM, Panse JP, Chauncey TR et al. High doses of transplanted CD34+ cells are associated with rapid T-cell engraftment and lessened risk of graft rejection, but not more graft-versus-host disease after nonmyeloablative conditioning and unrelated hematopoietic cell transplantation. Leukemia 2005; 19: 822-828.
Wang B, Nichol JL, Sullivan JT. Pharmacodynamics and pharmacokinetics of AMG 531, a novel thrombopoietin receptor ligand. Clin Pharmacol Ther 2004; 76: 628-638.